PCA
KURA icon

Pallas Capital Advisors’s Kura Oncology KURA Stock Holding History

Pallas Capital Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Buy
25,059
+3,645
+17% +$34.4K 0.01% 767
2026
Q1 		$174K Sell
21,414
-8,775
-29% -$75.4K 0.01% 779
2025
Q4 		$314K Buy
30,189
+6,112
+25% +$64.1K 0.01% 666
2025
Q3 		$213K Buy
24,077
+10,773
+81% +$76.8K 0.01% 767
2025
Q2 		$76.8K Buy
13,304
+3,241
+32% +$19.9K ﹤0.01% 808
2025
Q1 		$66.4K Buy
+10,063
New +$78.4K ﹤0.01% 720

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Pallas Capital Advisors's KURA Position: Q2 2026 in Review

Pallas Capital Advisors increased its Kura Oncology (KURA) stake by 17% in Q2 2026, buying an estimated $34.4K and bringing the position to 25,059 shares worth $275K. The position accounts for 0.01% of the portfolio, ranked #767.

Pallas Capital Advisors first reported a position in KURA in Q1 2025 and has held it in 6 quarters since. The position peaked at $314K in Q4 2025. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Pallas Capital Advisors held 25,059 shares of Kura Oncology worth $275K as of Q2 2026.
  • Pallas Capital Advisors bought 3,645 Kura Oncology shares in Q2 2026, an estimated $34.4K.
  • Kura Oncology made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #767 holding.
  • Pallas Capital Advisors first reported a position in Kura Oncology in Q1 2025 and has held it in 6 quarters since.
  • Pallas Capital Advisors's Kura Oncology position peaked at $314K in Q4 2025.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.